AegirBio AB Logo

AegirBio AB

Develops user-friendly, saliva-based tests for health monitoring & therapeutic drug monitoring.

AEGIR | ST

Overview

Corporate Details

ISIN(s):
SE0014401121 (+3 more)
LEI:
549300MWGS283WZLYI10
Country:
Sweden
Address:
Scheelevägen 27, 223 63 Lund
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Magnasense AB, formerly AegirBio AB, is a diagnostics company specializing in developing innovative, saliva-based solutions for health monitoring. The company's core technology platform enables the creation of user-friendly, non-invasive tests for personalized diagnostics. Magnasense focuses on preventative care, such as oral health, and chronic disease management, particularly through Therapeutic Drug Monitoring (TDM) to optimize the dosage of biological drugs. Its products are designed for both professional healthcare settings and at-home use, aiming to make precision diagnostic testing more accessible, simple, and convenient for individuals and providers.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all AegirBio AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for AegirBio AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for AegirBio AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-04-04 Bradley Messmer Other Other 499,829 N/A
2023-01-16 Fredrik Häglund Other Other 45,244 85,511.16 SEK
2022-12-09 Raphaela Heussen Other Other 37,689 N/A
2021-10-27 Martin Linde Other Other 370,000 N/A
2021-10-26 Anders Ingvarsson Other Other 120,000 N/A
2021-09-22 Patrik Elfwing Other Buy 2,000 519,200.00 SEK
2021-09-16 Anders Ingvarsson Other Other 120,000 N/A
2021-06-28 Gunnar Telhammar Other Sell 460 47,288.00 SEK
2021-06-17 Fredrik Häglund Other Other 245,397 1,840,477.50 SEK
2021-06-17 Martin Linde Other Other 160,263 1,169,919.90 SEK

Peer Companies

Lexaria Bioscience Corp. Logo
Biotech firm with patented technology improving oral drug delivery and absorption.
United States of America
LEXX
Lexeo Therapeutics, Inc. Logo
Develops AAV gene therapies for genetic cardiovascular and Alzheimer's diseases.
United States of America
LXEO
LEXICON PHARMACEUTICALS, INC. Logo
Develops gene-based drugs for chronic diseases, including treatments for heart failure.
United States of America
LXRX
LIFECORE BIOMEDICAL, INC. \DE\ Logo
A CDMO for parenteral drugs, producing injectable-grade sodium hyaluronate (HA).
United States of America
LFCR
Liminatus Pharma, Inc. Logo
Clinical-stage immuno-oncology firm developing cancer therapies targeting the CD47 checkpoint.
United States of America
LIMN
Lineage Cell Therapeutics Inc. Logo
Developing off-the-shelf cell therapies for neurological and ophthalmic conditions.
Israel
LCTX
Lipigon Pharmaceuticals AB Logo
Develops novel drugs for lipid metabolism disorders to reduce cardiovascular disease risk.
Sweden
LPGO
Lipocine Inc. Logo
Biopharma developing oral drugs for metabolic & endocrine disorders using delivery technology.
United States of America
LPCN
Lipum AB Logo
Develops first-in-class antibody treatments for chronic inflammatory diseases like arthritis.
Sweden
LIPUM
Liquidia Corp Logo
Develops inhaled therapies for rare cardiopulmonary diseases using proprietary PRINT® technology.
United States of America
LQDA

Talk to a Data Expert

Have a question? We'll get back to you promptly.